publication date: Jul. 10, 2015

Britten Named Hematology/Oncology Director at Medical University of South Carolina 


CAROLYN BRITTEN was named director of the Hematology/Oncology Division at the Medical University of South Carolina. She will continue her role as associate director for clinical investigations at the MUSC Hollings Cancer Center.

Britten was recruited to MUSC in 2012 from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, where she held several leadership positions from 2001 to 2012, including associate director of the Signal Transduction and Therapeutics Research Program.

She also holds the Charles Westfield Coker Endowed Chair in GI Oncology at MUSC, part of the South Carolina SmartState Centers of Excellence. Britten has a portfolio of more than 20 actively accruing trials for patients with advanced cancer.

Originally from Canada, Britten received her medical degree from the University of Toronto, and completed internship, residency and chief residency at the University of Western Ontario. She subsequently trained in medical oncology at the University of British Columbia in Vancouver, and completed a research fellowship in cancer drug development at the Institute for Drug Development at the University of Texas at San Antonio. She then joined the faculty at UCLA, where she developed their solid tumor phase I clinical trials program.

In addition to her phase I clinical trials expertise, she specializes in the treatment of gastrointestinal cancers. Britten has served on multiple committees for the American Society of Clinical Oncology and is highly active in national oncology networks. She recently co-led Hollings Cancer Center’s effort to become one of 12 sites funded … Continue reading 41-27 Britten Named Hematology/Oncology Director at Medical University of South Carolina

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.